Archive: Company News
Omnix Medical Secures $25 Million in Series C Funding Co-Led by Harel Insurance & Finance and the EIC Fund
— Existing and new investors joining forces to support the accelerated development of Omnix´s novel, first-in-class antimicrobials pipeline
— Funding underlines urgent global need for novel, resistance-proof antimicrobials
Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, announced today that it raised $25 million in a Series C funding round co-led by Harel Insurance & Finance and the EIC Fund. Existing shareholders Entree Capital, Tal Ventures, Xenia Ventures, and Oriella Limited demonstrated strong confidence in Omnix’s approach by taking part in the round alongside new external investors, including Prevail Partners and OurCrowd.
Stanford University Secures NIH Grant to Advance tiakis Biotech´s Elafin (Tiprelestat) Through a U.S. Phase II Trial in Pulmonary Arterial Hypertension
– Novel, disease-modifying treatment option for Pulmonary Arterial Hypertension (PAH), an orphan indication with a significant unmet medical need
Kiel, GERMANY, September 8, 2025 – tiakis Biotech AG (“tiakis”), a clinical-stage biopharmaceutical company developing novel therapeutics for life-threatening pulmonary and cardiovascular diseases, today announced that its long-standing collaboration partner Stanford University has been awarded a US$ double-digit million grant from the National Institutes of Health (NIH) – National Heart Lung and Blood Institute (NHLBI) – the Lung Division, to fund a U.S. Phase II trial of Tiprelestat for the treatment of Pulmonary Arterial Hypertension (PAH). Read more…
BellaSeno Establishes High-Profile Clinical Advisory Board
— Leading international experts to support clinical development of BellaSeno´s pioneering resorbable breast implants
— Pivotal clinical trial to be initiated shortly
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced that the Company has established a Clinical Advisory Board consisting of seven renowned key opinion leaders (KOLs) in the fields of clinical breast reconstruction and plastic surgery. Read more…
Mabylon AG Raises CHF 30 Million to Advance Peanut Allergy Lead Program MY006 to Clinical Proof-of-Concept
— Funding combines equity investment and convertible loan
— Focus on best-in-class, clinical-stage peanut allergen neutralizing antibody
— Further potential for developing Mabylon’s discovery and pre-clinical pipeline programs
— Thomas Hecht has joined Board of Directors
Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has raised a total of CHF 30 million (USD 37 million) to further develop its clinical-stage lead candidate MY006 and advance its early-stage pipeline. The funding combines a capital increase and a convertible loan of CHF 15 million, respectively. The funds are provided by Mabylon’s existing private investors, with the major investment coming from former management and board members of Roche. Read more…